Kyverna Therapeutics Inc (KYTX) Stock Price, Quote & News

Company Profile

Kyverna Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome, myasthenia gravis, and autoimmune diseases. The company is also developing KYV-102, an autologous CD19 CAR T-cell product candidate with whole blood rapid manufacturing; and KYV-201, an allogeneic CD19 CAR T-cell product cand...

Industry: Biotechnology

Sector: Healthcare

Phone: 510 925 2492

Website: kyvernatx.com

Address:

5980 Horton Street, Suite 550, Emeryville, United States

ZackInvest008 Jul. 16 at 2:57 PM

$KYTX Where's support now? No such thing as a triple bottom, so 6.50 before it bonces?

1 · Reply

HarryScrotmmm Jul. 15 at 8:06 PM

$KYTX anyone think the week agp run to the 10s was MM's doing it for the company so they could hit the atm ?

1 · Reply

Strat Jul. 14 at 10:25 PM

$KYTX Biggest reason for latest drop per Gemini was Macro Sector Profit-Taking ("A Hot Trade")Prior to the drop, KYTX was a heavily crowded trade, up roughly 25% over the trailing month and over 215% over the past year. When a low-float, high-beta stock experiences that level of rapid growth, institutional investors look for any technical trigger to log profits. The small JPMorgan price target trim (from $30 down to $29) acted as a psychological trigger rather than a fundamental downgrade, prompting algorithms and funds to cascade sell orders to take profits. So it was JPM triggering this really with their cheesy dollar downgrade. Nothing has changed fundamentally.

1 · Reply

TNNStockAnalysisNews Jul. 14 at 3:55 AM

10 Stocks to Watch Tomorrow — Tuesday, July 14 $FAST - Reports: Tuesday, July 14 — Before Open | EPS Est: $0.33 | Revenue Est: +12.6% YoY $C - Reports: Tuesday Before Open | YTD Performance: +18.9% | Sector Leader $WFC - Reports: Tuesday Before Open | YTD: −7.2% (Worst of 5) | EPS Est: $1.72 (+7.5% YoY) | Revenue Est: $21.85B (+4.9% YoY) $KYTX - Current Price: ~$8.60 | 52-Week Range: $1.78 – $13.67 | Market Cap: ~$520M | Beta: 1.88 $MDGL - Today’s Move: +4.16% | StockTwits Trending #9 | Q1 2026 Revenue: $311.34M (+127% YoY) https://truthsandnews.com/markets/stocks-to-watch-tomorrow-july-14-2026-cpi-bank-earning

0 · Reply

BioRich Jul. 13 at 11:51 PM

$RGNX $SGP $EWTX $BIOA and $KYTX "Sound the Rebound" picks for tomorrow. Looks like simple market collateral damage today and don't see anything in any of these that would justify being down this far (unless of course I missed something. Follow/Subscribe for more suggestions and perspective. Would love to hear yours too. That's how we find these gems and learn. Let's makes some (more) money. Cheers!

0 · Reply

bernardbaruch Jul. 13 at 11:20 PM

$KYTX bot 1500 AH @ $7.79 to hold 1500 NIA

3 · Reply

Strat Jul. 13 at 11:18 PM

$KYTX I bought light . Got a few hundred more shares at $7.92 area. This is so typical of bio's like this when there is really nothing going on and nothing changed fundamentally. This company is solid and has a basket of good platforms brewing for autoimmune. The mid-summer swoon is here. I fully expect this to start going back up as we start to approach Sept. and start to see the BLA come to completion - or at least getting the pieces in. In the meantime, I will continue to add when it hits areas that look attractive.

0 · Reply

GSTX7 Jul. 13 at 5:53 PM

$KYTX Back in after selling the last pop at 9.94.

0 · Reply

bioisrisky Jul. 13 at 5:44 PM

$KYTX 20% down in 2.5 trading days. Going to start legging in here but cautiously.

0 · Reply

bioland Jul. 13 at 5:31 PM

$KYTX More stops will be hit soon...unreal

1 · Reply

Kyverna Therapeutics appoints Ritesh Srivastava chief legal, compliance officer

Jun 22, 2026, 8:00 AM EDT - 24 days ago

Kyverna Therapeutics Appoints Ritesh Srivastava as Chief Legal and Compliance Officer, Adding Leadership Strength to Support Commercial-Stage Transition

Jun 3, 2026, 3:10 PM EDT - 6 weeks ago

Kyverna Therapeutics Transcript: Jefferies Global Healthcare Conference 2026

2026-06-03T13:00:42.000Z - 6 weeks ago

Kyverna Therapeutics presents updated COMPARE trial data at EULAR

$Kyverna Therapeutics Highlights Updated Miv-cel Data at EULAR Demonstrating Substantial Reduction in Disease Activity in ACPA-Positive, Treatment Refractory Rheumatoid Arthritis$

Jun 3, 2026, 8:00 AM EDT - 6 weeks ago

Kyverna Therapeutics Highlights Updated Miv-cel Data at EULAR Demonstrating Substantial Reduction in Disease Activity in ACPA-Positive, Treatment Refractory Rheumatoid Arthritis

Jun 3, 2026, 7:00 AM EDT - 6 weeks ago

Kyverna Therapeutics Slides: Corporate presentation

May 27, 2026, 2:00 PM EDT - 7 weeks ago

Kyverna Therapeutics Transcript: AGM 2026

May 19, 2026, 2:30 PM EDT - 2 months ago

Kyverna Therapeutics Transcript: H.C. Wainwright 4th Annual BioConnect Investor Conference

2026-05-18T12:16:11.000Z - 2 months ago

Kyverna Therapeutics CFO Marc Grasso to step down, Greg Martini to succeed

IRWD

May 18, 2026, 8:00 AM EDT - 2 months ago

Kyverna Therapeutics Names Greg Martini as Chief Financial Officer

2026-05-15T10:20:21.000Z - 2 months ago

Kyverna Therapeutics price target raised to $25 from $20 at H.C. Wainwright

May 14, 2026, 8:00 AM EDT - 2 months ago

Kyverna Therapeutics to Present at Upcoming Investor Conferences

2026-05-13T11:20:39.000Z - 2 months ago

Kyverna Therapeutics price target lowered to $29 from $30 at JPMorgan

2026-05-12T22:38:44.000Z - 2 months ago

Kyverna Therapeutics reports Q1 EPS (66c), consensus (73c)

May 12, 2026, 4:02 PM EDT - 2 months ago

Kyverna Therapeutics Announces Initiation of Rolling SPS BLA Submission and Reports First Quarter 2026 Financial Results

May 12, 2026, 4:00 PM EDT - 2 months ago

Kyverna Therapeutics Earnings release: Q1 2026

May 12, 2026, 4:00 PM EDT - 2 months ago

Kyverna Therapeutics Quarterly report: Q1 2026

May 12, 2026, 7:00 AM EDT - 2 months ago

Kyverna Therapeutics Slides: Investor presentation

2026-05-04T12:45:05.000Z - 2 months ago

Kyverna Therapeutics appoints Nadia Dac as chief commercial officer

OMER

May 4, 2026, 8:00 AM EDT - 2 months ago

Kyverna Therapeutics Appoints Nadia Dac, Seasoned Commercial Leader in Neurology and Rare Disease, as Chief Commercial Officer

Apr 22, 2026, 7:00 AM EDT - 3 months ago

Kyverna Therapeutics Transcript: Status update

Apr 22, 2026, 7:00 AM EDT - 3 months ago

Kyverna Therapeutics Press release: Status update

Apr 22, 2026, 7:00 AM EDT - 3 months ago

Kyverna Therapeutics Slides: Status update

2026-04-21T22:50:16.000Z - 3 months ago

Kyverna Therapeutics reports ‘positive’ results from KYSA-8 trial of miv-cel

Apr 21, 2026, 6:45 PM EDT - 3 months ago

Kyverna Presents Registrational Trial Primary Analysis for Miv-cel in Stiff Person Syndrome Demonstrating Statistically Significant, Durable Clinical Benefit Across All Endpoints in an Oral, Late-Breaker Session at AAN Annual Meeting

2026-04-20T13:12:24.000Z - 3 months ago

Kyverna Therapeutics presents longer-term Phase 2 data for Miv-cel

Apr 20, 2026, 8:00 AM EDT - 3 months ago

Kyverna Presents Longer-Term Phase 2 Data for Miv-cel in Generalized Myasthenia Gravis at AAN, Demonstrating Deep, Durable Responses through 52 Weeks

Apr 13, 2026, 8:00 AM EDT - 3 months ago

Kyverna Therapeutics Proxy statement: Proxy filing

Apr 13, 2026, 8:00 AM EDT - 3 months ago

Kyverna Therapeutics Proxy statement: Proxy filing

Apr 9, 2026, 8:00 AM EDT - 3 months ago

Kyverna Therapeutics to Host Conference Call on New Data Across Neuroimmunology Franchise at AAN 2026

2026-03-26T20:25:22.000Z - 4 months ago

Kyverna Therapeutics files $300M mixed securities shelf

2026-03-26T20:12:42.000Z - 4 months ago

Kyverna Therapeutics reports Q4 EPS (80c), consensus (86c)

Mar 26, 2026, 4:02 PM EDT - 4 months ago

Kyverna Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results

Mar 26, 2026, 4:00 PM EDT - 4 months ago

Kyverna Therapeutics Annual report: Q4 2025

Mar 26, 2026, 4:00 PM EDT - 4 months ago

Kyverna Therapeutics Earnings release: Q4 2025

Mar 26, 2026, 8:00 AM EDT - 4 months ago

Kyverna Therapeutics Registration statement: Registration filing

Mar 26, 2026, 7:00 AM EDT - 4 months ago

Kyverna Therapeutics Slides: Corporate presentation

Mar 9, 2026, 11:20 AM EDT - 4 months ago

Kyverna Therapeutics Transcript: Leerink Global Healthcare Conference 2026

Mar 5, 2026, 4:21 PM EST - 4 months ago

Kyverna Therapeutics to Present New Data from Neuroimmunology Franchise at AAN 2026

Mar 3, 2026, 8:00 AM EST - 4 months ago

Kyverna Therapeutics to Participate in Upcoming March Investor Conferences

2026-02-24T13:20:34.000Z - 5 months ago

Kyverna Therapeutics appoints Sravan Emany, Andrew Miller to board

BEAM

Feb 24, 2026, 8:00 AM EST - 5 months ago

Kyverna Therapeutics Appoints Biotech Leaders Sravan Emany and Andrew Miller to Board of Directors

2026-02-03T13:25:38.000Z - 5 months ago

Kyverna Therapeutics appoints Pujols as Chief Technology Officer

Feb 3, 2026, 8:00 AM EST - 5 months ago

Kyverna Therapeutics Appoints Mayo Pujols as Chief Technology Officer

Jan 14, 2026, 12:45 PM EST - 6 months ago

Kyverna Therapeutics Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 14, 2026, 12:45 PM EST - 6 months ago

Kyverna Therapeutics Slides: 44th Annual J.P. Morgan Healthcare Conference

2026-01-12T13:38:56.000Z - 6 months ago

Kyverna Therapeutics provides corporate update, priorities for 2026

Jan 12, 2026, 8:00 AM EST - 6 months ago

Kyverna Therapeutics Provides Corporate Update and Outlines 2026 Strategic Priorities at the J.P. Morgan Healthcare Conference

Jan 12, 2026, 7:00 AM EST - 6 months ago

Kyverna Therapeutics Slides: Investor presentation

Jan 5, 2026, 8:00 AM EST - 6 months ago

Kyverna Therapeutics to Present at the J.P. Morgan 2026 Healthcare Conference

2025-12-17T14:30:20.000Z - 7 months ago

Kyverna prices 13.3M shares at $7.50 in underwritten public offering

Dec 17, 2025, 9:24 AM EST - 7 months ago

Kyverna Therapeutics Announces Pricing of $100 Million Public Offering of Common Stock

2025-12-16T11:51:24.000Z - 7 months ago

Kyverna Therapeutics price target raised to $33 from $31 at Wells Fargo

Dec 15, 2025, 4:01 PM EST - 7 months ago

Kyverna Therapeutics Announces Proposed Public Offering of Common Stock

Dec 15, 2025, 8:00 AM EST - 7 months ago

Kyverna Therapeutics Transcript: Study Result

Dec 15, 2025, 8:00 AM EST - 7 months ago

Kyverna Therapeutics Press release: Study Result

Dec 15, 2025, 8:00 AM EST - 7 months ago

Kyverna Therapeutics Slides: Study Result

Dec 15, 2025, 6:42 AM EST - 7 months ago

Kyverna's cell therapy meets main goal of mid-stage study

Dec 15, 2025, 6:30 AM EST - 7 months ago

Kyverna Therapeutics Announces Positive Topline Data from Registrational KYSA-8 Trial of Miv-cel (KYV-101) in Stiff Person Syndrome

Dec 14, 2025, 2:30 PM EST - 7 months ago

Kyverna Therapeutics to Report Topline Results from Registrational Phase 2 KYSA-8 Trial of KYV-101 in Stiff Person Syndrome

Nov 17, 2025, 8:00 AM EST - 8 months ago

Kyverna Therapeutics Transcript: Jefferies London Healthcare Conference 2025

Nov 12, 2025, 4:05 PM EST - 8 months ago

Kyverna Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results

Nov 12, 2025, 7:00 AM EST - 8 months ago

Kyverna Therapeutics Earnings release: Q3 2025

Nov 12, 2025, 7:00 AM EST - 8 months ago

Kyverna Therapeutics Quarterly report: Q3 2025

Nov 10, 2025, 8:00 AM EST - 8 months ago

Kyverna Therapeutics to Present at the Jefferies London Healthcare Conference

Nov 3, 2025, 8:00 AM EST - 9 months ago

Kyverna Therapeutics Secures up to $150 Million in Non-Dilutive Financing from Oxford Finance

Oct 29, 2025, 8:00 AM EDT - 9 months ago

Kyverna Therapeutics Transcript: Study Update

Oct 29, 2025, 8:00 AM EDT - 9 months ago

Kyverna Therapeutics Press release: Study Update

Oct 29, 2025, 8:00 AM EDT - 9 months ago

Kyverna Therapeutics Slides: Study Update

Oct 29, 2025, 6:30 AM EDT - 9 months ago

Kyverna Therapeutics Announces Positive Interim Phase 2 Data from KYSA-6 Study of KYV-101 in Generalized Myasthenia Gravis at AANEM 2025

Oct 25, 2025, 11:00 AM EDT - 9 months ago

Kyverna Therapeutics Highlights Potential of KYV-101 in Rheumatoid Arthritis with Phase 1 Data from Investigator-Initiated Trial Presented at ACR Convergence 2025

Oct 22, 2025, 8:00 AM EDT - 9 months ago

Kyverna Therapeutics to Host Conference Call on Interim Phase 2 Data from KYSA-6 Study of KYV-101 in Generalized Myasthenia Gravis

Sep 24, 2025, 9:05 AM EDT - 10 months ago

Kyverna Therapeutics Highlights Potential of KYV-101 in Multiple Sclerosis with Data from Phase 1 Investigator-Initiated Trials to be Presented at ECTRIMS

Sep 15, 2025, 1:02 PM EDT - 10 months ago

Kyverna Therapeutics to Highlight Interim Phase 2 Data from KYV-101 KYSA-6 Study in Myasthenia Gravis at AANEM 2025

Sep 9, 2025, 11:00 AM EDT - 11 months ago

Kyverna Therapeutics Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 8, 2025, 4:05 PM EDT - 11 months ago

Kyverna Therapeutics Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Sep 3, 2025, 11:00 AM EDT - 11 months ago

Kyverna Therapeutics Transcript: Wells Fargo 20th Annual Healthcare Conference 2025

Aug 28, 2025, 11:00 AM EDT - 11 months ago

Kyverna Therapeutics Transcript: KOL Event

Aug 28, 2025, 11:00 AM EDT - 11 months ago

Kyverna Therapeutics Press release: KOL Event

Aug 28, 2025, 11:00 AM EDT - 11 months ago

Kyverna Therapeutics Slides: KOL Event

Aug 28, 2025, 8:00 AM EDT - 11 months ago

Kyverna Therapeutics Highlights Neuroimmunology CAR T Franchise and Registrational Phase 3 Trial Design in Myasthenia Gravis at Virtual KOL Event

Aug 25, 2025, 4:02 PM EDT - 11 months ago

Kyverna Therapeutics to Present at Upcoming Investor Conferences in September

Aug 12, 2025, 4:02 PM EDT - 1 year ago

Kyverna Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results

Aug 12, 2025, 4:00 PM EDT - 1 year ago

Kyverna Therapeutics Quarterly report: Q2 2025

Aug 12, 2025, 4:00 PM EDT - 1 year ago

Kyverna Therapeutics Earnings release: Q2 2025

Jul 29, 2025, 8:30 AM EDT - 1 year ago

Kyverna Therapeutics to Host Virtual KOL Event to Highlight Neuroimmunology CAR T Franchise

Jun 4, 2025, 4:55 PM EDT - 1 year ago

Kyverna Therapeutics Transcript: Jefferies Global Healthcare Conference 2025

May 28, 2025, 4:02 PM EDT - 1 year ago

Kyverna Therapeutics to Present at the Jefferies Global Healthcare Conference

May 13, 2025, 4:02 PM EDT - 1 year ago

Kyverna Therapeutics Provides Business Update and Reports First Quarter 2025 Financial Results

May 12, 2025, 4:00 PM EDT - 1 year ago

Kyverna Therapeutics Quarterly report: Q1 2025

May 12, 2025, 4:00 PM EDT - 1 year ago

Kyverna Therapeutics Earnings release: Q1 2025

Apr 14, 2025, 8:00 AM EDT - 1 year ago

Kyverna Therapeutics Proxy statement: Proxy Filing

Apr 14, 2025, 8:00 AM EDT - 1 year ago

Kyverna Therapeutics Proxy statement: Proxy Filing

Mar 27, 2025, 4:02 PM EDT - 1 year ago

Kyverna Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results

Mar 27, 2025, 4:00 PM EDT - 1 year ago

Kyverna Therapeutics Annual report: Q4 2024

Mar 27, 2025, 4:00 PM EDT - 1 year ago

Kyverna Therapeutics Earnings release: Q4 2024

Mar 27, 2025, 8:00 AM EDT - 1 year ago

Kyverna Therapeutics Registration statement: Registration Filing

Mar 10, 2025, 3:00 PM EDT - 1 year ago

Kyverna Therapeutics Transcript: Leerink’s Global Healthcare Conference 2025

Mar 3, 2025, 4:05 PM EST - 1 year ago

Kyverna Therapeutics to Present at the Leerink Partners Global Biopharma Conference

Feb 7, 2025, 11:42 AM EST - 1 year ago

KYTX Deadline: KYTX Investors Have Opportunity to Lead Kyverna Therapeutics, Inc. Securities Lawsuit

ZackInvest008 Jul. 16 at 2:57 PM

$KYTX Where's support now? No such thing as a triple bottom, so 6.50 before it bonces?

1 · Reply

HarryScrotmmm Jul. 15 at 8:06 PM

$KYTX anyone think the week agp run to the 10s was MM's doing it for the company so they could hit the atm ?

1 · Reply

Strat Jul. 14 at 10:25 PM

1 · Reply

TNNStockAnalysisNews Jul. 14 at 3:55 AM

0 · Reply

BioRich Jul. 13 at 11:51 PM

0 · Reply

bernardbaruch Jul. 13 at 11:20 PM

$KYTX bot 1500 AH @ $7.79 to hold 1500 NIA

3 · Reply

Strat Jul. 13 at 11:18 PM

0 · Reply

GSTX7 Jul. 13 at 5:53 PM

$KYTX Back in after selling the last pop at 9.94.

0 · Reply

bioisrisky Jul. 13 at 5:44 PM

$KYTX 20% down in 2.5 trading days. Going to start legging in here but cautiously.

0 · Reply

bioland Jul. 13 at 5:31 PM

$KYTX More stops will be hit soon...unreal

1 · Reply

Astrobro Jul. 13 at 4:20 PM

$KYTX Adding here is a no brainer.

0 · Reply

Madmortigan Jul. 13 at 1:52 PM

$KYTX We buying more?

1 · Reply

TNNStockAnalysisNews Jul. 13 at 2:40 AM

10 Stocks to Watch Tomorrow — Monday, July 13, 2026: Earnings Season Ignites, CAR-T Recovers, and the Big Bank Countdown Begins $FAST — Monday Morning’s First Earnings Signal of the Season $KYTX — 13% Drop on Friday. The Recovery Thesis Starts Monday $TMUS — BofA Pulls the Trigger With a Buy and $220 Target $FBK — The Small Regional Bank Reporting Monday $WFC — The Most Important Tuesday Positioning Trade https://truthsandnews.com/markets/stocks-to-watch-tomorrow-july-13-2026-fast-kytx-more

0 · Reply

rispi Jul. 11 at 6:41 AM

$KYTX when is next readout scheduled?

0 · Reply

bioland Jul. 10 at 8:01 PM

$KYTX No recovery is a little concerning.

4 · Reply

Jhoooon Jul. 10 at 5:37 PM

$DRTS $SLS $IBRX $ABVX $KYTX

3 · Reply

BioRich Jul. 10 at 4:55 PM

$XBI Rough day for Bios. Looks like we're seeing a bit of a turnaround but a solid stress test. Looking for $KYTX, $RGNX, $IBRX and $EWTX all being massive opportunities after this pull back. Follow/Subscribe for more suggestions and perspective. Would love to hear yours too. That's how we find these gems and learn. Let's make some (more) money. Cheers!

0 · Reply